Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Preceptorship on Metastatic Bladder and Kidney Cancer 2022

ESMO-Preceptorship-Metastatic and Kidney Cancer-2022-1000x250-july
Start date
11 Jul 2022
End date
12 Jul 2022
Location
Lugano, Switzerland

Learning objectives

  • To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
  • To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
  • To learn about advances in treatment and novel targets in bladder and kidney cancer

Download the programme

Accreditation

The programme of this event has been accredited with 10 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.

Co-Chairs

  • Laurence Albiges, France
  • Viktor Grünwald, Germany

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.